Clinical Trial Detail

NCT ID NCT04296942
Title BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor positive breast cancer

Therapies

FPV-Brachyury + M7824 + MVA-BN-Brachyury

Ado-trastuzumab emtansine + Entinostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury

Ado-trastuzumab emtansine + FPV-Brachyury + M7824 + MVA-BN-Brachyury

Age Groups: adult senior

Additional content available in CKB BOOST